Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOMEA FUSION, INC.

(BMEA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
11.73(c) 10.74(c) 9.8(c) 10.195(c) 10.59 Last
101 696 82 907 87 025 135 453 10 348 Volume
-2.82% -8.44% -8.75% +4.03% +3.87% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -40,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,98x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -77,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,84x
Yield 2022 -
Capitalization 296 M 296 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 47
Free-Float 66,4%
More Financials
Company
Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is... 
More about the company
All news about BIOMEA FUSION, INC.
11/15BIOMEA FUSION : tm Corporate Presentation November 2021 - Form 8-K
PU
11/15BIOMEA FUSION, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
11/10Biomea Fusion to Participate in Two Upcoming Investor Conferences
AQ
11/04Biomea Fusion Publishes Abstract on BMF-219 at ASH Annual Meeting
GL
11/04Biomea Fusion Publishes Abstract on BMF-219 at ASH Annual Meeting
GL
11/04Biomea Fusion, Inc. Publishes Abstract on BMF-219 at ASH Annual Meeting
CI
11/03Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights - Fo..
PU
11/03BIOMEA FUSION, INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/03Earnings Flash (BMEA) BIOMEA FUSION Posts Q3 Loss $-0.43
MT
11/03Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights
AQ
10/1319,767,867 Common Stock of Biomea Fusion, Inc. are subject to a Lock-Up Agreement Endin..
CI
10/13Certain Stock Options of Biomea Fusion, Inc. are subject to a Lock-Up Agreement Ending..
CI
09/21INSIDER BUY : Biomea Fusion
MT
09/20BIOMEA FUSION, INC.(NASDAQGS : BMEA) added to S&P Global BMI Index
CI
09/17BIOMEA FUSION : Announces FDA Clearance of Investigational New Drug Application for Irreve..
PU
More news
News in other languages on BIOMEA FUSION, INC.
09/16Biomea Fusion obtient l'autorisation de la FDA de lancer un essai de phase précoce du B..
06/29Biomea Fusion nomme Franco Valle directeur financier
05/28Biomea Fusion affiche une perte plus importante au premier trimestre
04/16Biomea fait un bond à l'ouverture lors de ses débuts au Nasdaq
More news
Analyst Recommendations on BIOMEA FUSION, INC.
More recommendations
Chart BIOMEA FUSION, INC.
Duration : Period :
Biomea Fusion, Inc. Technical Analysis Chart | BMEA | US09077A1060 | MarketScreener
Technical analysis trends BIOMEA FUSION, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 10,20 $
Average target price 26,00 $
Spread / Average Target 155%
EPS Revisions
Managers and Directors
Thomas Butler Chairman & Chief Executive Officer
Rainer M. Erdtmann President
Franco Valle Chief Financial & Accounting Officer
Heow Tan Chief Technology & Quality Officer
Anthony Souza Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
BIOMEA FUSION, INC.0.00%296
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-42.48%23 888